These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 29410340)

  • 1. Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation.
    Epperla N; Hamadani M; Ahn KW; He F; Kodali D; Kleman A; Hari PN; Pasquini M; Fenske TS; Craig MD; Kanate AS; Bachanova V
    Biol Blood Marrow Transplant; 2018 May; 24(5):983-988. PubMed ID: 29410340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.
    Ram R; Gooley TA; Maloney DG; Press OW; Pagel JM; Petersdorf SH; Shustov AR; Flowers ME; O'Donnell P; Sandmaier BM; Storb RF; Gopal AK
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1537-45. PubMed ID: 21536145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
    Htut M; D'Souza A; Krishnan A; Bruno B; Zhang MJ; Fei M; Diaz MA; Copelan E; Ganguly S; Hamadani M; Kharfan-Dabaja M; Lazarus H; Lee C; Meehan K; Nishihori T; Saad A; Seo S; Ramanathan M; Usmani SZ; Gasparetto C; Mark TM; Nieto Y; Hari P
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):478-485. PubMed ID: 29079457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
    Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
    Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
    Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.
    Wudhikarn K; Brunstein CG; Bachanova V; Burns LJ; Cao Q; Weisdorf DJ
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1497-504. PubMed ID: 21338707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
    Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
    Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
    Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival.
    Ertz-Archambault N; Kosiorek H; Slack JL; Lonzo ML; Greipp PT; Khera N; Kelemen K
    Biol Blood Marrow Transplant; 2017 May; 23(5):782-789. PubMed ID: 28189903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors for Postrelapse Survival after ex Vivo CD34
    Gomez-Arteaga A; Shah GL; Baser RE; Scordo M; Ruiz JD; Bryant A; Dahi PB; Ghosh A; Lahoud OB; Landau HJ; Landgren O; Shaffer BC; Smith EL; Koehne G; Perales MA; Giralt SA; Chung DJ
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2040-2046. PubMed ID: 32712326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
    Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T
    Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT.
    Badar T; Epperla N; Szabo A; Borson S; Vaughn J; George G; Saini N; Shah AR; Patel RD; Ahmed S; Shah NN; Cashen AF; Hamadani M; Fenske TS
    Blood Adv; 2020 Jan; 4(1):47-54. PubMed ID: 31899797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients.
    Montefusco V; Mussetti A; Rezzonico F; Maura F; Pennisi M; de Philippis C; Capecchi M; Corradini P
    Bone Marrow Transplant; 2017 Dec; 52(12):1602-1608. PubMed ID: 28892086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.
    Epperla N; Badar T; Szabo A; Vaughn J; Borson S; Saini NY; Patel RD; Shah NN; Hamadani M; Ahmed S; Cashen AF; Fenske TS
    Blood Adv; 2019 Jun; 3(11):1661-1669. PubMed ID: 31167818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma.
    Inoue Y; Fuji S; Tanosaki R; Inamoto Y; Tanaka T; Ito A; Okinaka K; Kurosawa S; Kim SW; Nakagama H; Fukuda T
    Bone Marrow Transplant; 2018 Sep; 53(9):1105-1115. PubMed ID: 29523883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.
    Afrough A; Alsfeld LC; Milton DR; Delgado R; Popat UR; Nieto Y; Kebriaei P; Oran B; Saini N; Srour S; Hosing C; Cheema FH; Ahmed S; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Weber DM; Orlowski RZ; Pinnix CC; Dabaja BS; Thomas SK; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
    Transplant Cell Ther; 2023 Apr; 29(4):264.e1-264.e9. PubMed ID: 35605883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
    Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years.
    Bazarbachi A; Schmid C; Labopin M; Beelen D; Wolfgang Blau I; Potter V; Niittyvuopio R; Socié G; Blaise D; Sanz J; Ciceri F; Abou Dalle I; Spyridonidis A; Bug G; Esteve J; Savani BN; Nagler A; Mohty M
    Clin Cancer Res; 2020 Dec; 26(24):6475-6482. PubMed ID: 32988970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy.
    Zuanelli Brambilla C; Lobaugh SM; Ruiz JD; Dahi PB; Goldberg AD; Young JW; Gyurkocza B; Shaffer BC; Ponce DM; Tamari R; Sanchez Escamilla M; Castillo Flores N; Politikos I; Scordo M; Shah GL; Cho C; Lin RJ; Maloy MA; Devlin SM; Jakubowski AA; Berman E; Stein EM; Papadopoulos EB; Perales MA; Tallman MS; Giralt SA; Smith M
    Transplant Cell Ther; 2021 Sep; 27(9):771.e1-771.e10. PubMed ID: 34033977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.